Home Biosimilar Antibodies Immunology & Inflammation CD markers Ianalumab (Anti-TNFRSF13C / BAFFR / CD268)
For research use only. Not for use in humans.

Ianalumab (Anti-TNFRSF13C / BAFFR / CD268)

Synonyms: CD268,TNFRSF13C

Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.

Ianalumab (Anti-TNFRSF13C / BAFFR / CD268)

Quality Control

Batch: A232901 Purity: 99% Protein concentration: 5.402mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD.

Product Details

CAS No. 1929549-92-7
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06191887 RECRUITING Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Fludarabine B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia Mayo Clinic 2024-03-18 PHASE1
NCT06711887 RECRUITING Drug: Ianalumab Lupus Nephritis Novartis Pharmaceuticals 2025-05-19 PHASE3
NCT05985915 ACTIVE_NOT_RECRUITING Drug: Ianalumab (VAY736) Sjogrens Syndrome Novartis Pharmaceuticals 2023-10-27 PHASE3
NCT07660172 NOT_YET_RECRUITING Drug: Eltrombopag Primary Immune Thrombocytopenia (ITP) Novartis Pharmaceuticals 2027-02-08 PHASE2
NCT07039422 RECRUITING Primary Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia Novartis Pharmaceuticals 2026-06-26 PHASE2
NCT06133972 RECRUITING Drug: Placebo|Drug: Ianalumab Systemic Lupus Erythematosus Novartis Pharmaceuticals 2024-05-21 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-02-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.